Effects of steroidal and non‐steroidal antiandrogens on wild‐type and mutant androgen receptors
Authors:
- 20 March 2007
- journal article
- research article
- Published by Wiley in The Prostate
- Vol. 67 (8) , 799-807
Abstract
BACKGROUND: Molecular basis for secondary antiandrogen therapy in prostate cancer with mutant androgen receptors (ARs) is not fully elucidated.MATERIALS AND METHODS: Effects of steroidal and non‐steroidal antiandrogens on transcriptional activities of wild‐type and mutant (W741C, T877A, and W741C+T877A) ARs were measured. Crystal structure analysis and docking studies were performed using Molecular Operating Environment (MOE) package.RESULTS: DHT‐induced transcriptional activity of the T877A mutant and the W741C mutant was suppressed by bicalutamide and hydroxyflutamide, respectively. Nilutamide suppressed the W741C mutant and the double mutant. Cyproterone acetate modestly inhibited the W741C mutant and the double mutant. The structural studies suggested that nilutamide and cyproterone acetate retain their antiandrogenic properties against both the W741C mutant and the double mutant due to fact that mutation W741C does not permit formation of key hydrophobic interaction between ligand and AR ligand binding domain, which is necessary for their conversion into agonists.CONCLUSIONS: Switching antiandrogens may be reasonable in prostate cancer with mutant ARs. Prostate 67: 799–807, 2007.Keywords
This publication has 14 references indexed in Scilit:
- Antiandrogen Bicalutamide Promotes Tumor Growth in a Novel Androgen-Dependent Prostate Cancer Xenograft Model Derived from a Bicalutamide-Treated PatientCancer Research, 2005
- Clinical outcome of maximum androgen blockade using flutamide as second‐line hormonal therapy for hormone‐refractory prostate cancerBJU International, 2005
- Prolonged Response to Nilutamide in a Patient with Stage D0.5 Prostate Cancer Who Previously Failed Androgen Deprivation TherapyAmerican Journal of Therapeutics, 2005
- Regulation of prostate-specific antigen by activin A in prostate cancer LNCaP cellsAmerican Journal of Physiology-Endocrinology and Metabolism, 2004
- Androgen Receptor Mutations in Androgen-Independent Prostate Cancer: Cancer and Leukemia Group B Study 9663Journal of Clinical Oncology, 2003
- Nilutamide as Second Line Hormone Therapy for Prostate Cancer After Androgen Ablation FailsJournal of Urology, 2003
- Nilutamide: possible utility as a second-line hormonal agentUrology, 2001
- COMPLETE ANDROGEN BLOCKADE FOR PROSTATE CANCER: WHAT WENT WRONG?Journal of Urology, 2000
- Anti-androgens and the mutated androgen receptor of LNCaP cells: differential effects on binding affinity, heat-shock protein interaction, and transcription activationBiochemistry, 1992
- A mutation in the ligand binding domain of the androgen receptor of human INCaP cells affects steroid binding characteristics and response to anti-androgensBiochemical and Biophysical Research Communications, 1990